GenMark Diagnostics, Inc. (Nasdaq:GNMK) announced today that it has named Scott Mendel as Chief Financial Officer, effective May 13, 2014.
Mendel brings 25 years of public company financial leadership experience and a proven track record of leading highly-complex, global businesses. Mendel joins GenMark from Active Network, where he served for nearly four years as its Chief Financial Officer and provided financial leadership through their IPO, global restructuring, and subsequent sale to Vista Equity. Previously, he spent more than 20 years with General Electric, most recently as Chief Financial Officer of GE’s Healthcare IT division. Mendel succeeds Richard Slansky, who will leave the Company for personal reasons following an appropriate transition period.
“We are delighted to welcome Scott to the GenMark team,” said Hany Massarany, GenMark’s President and CEO. “With the upcoming introduction of our NexGen system, Scott’s broad business experience in global, high growth environments will be invaluable to GenMark as we further establish our leadership position in the global molecular diagnostics market.”
ABOUT GENMARK DIAGNOSTICSGenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark's proprietary eSensor ® detection technology, GenMark's eSensor ® XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets four tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory Viral Panel, Thrombophilia Risk Test, and Warfarin Sensitivity Test. A number of other tests, including HCV Genotyping, 2C19 Genotyping, and 3A4/3A5 Genotyping are available for research use only. For more information, visit www.genmarkdx.com. SAFE HARBOR STATEMENT This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding the timely completion of our NexGen system and related assay development projects, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, our ability to successfully develop and commercialize our NexGen system and its related test menu, constraints or inefficiencies caused by unanticipated acceleration and deceleration of customer demand, our ability to successfully expand sales of our product offerings outside the United States, and third-party payor reimbursement to our customers, as well as other risks and uncertainties described under the "Risk Factors" in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.